The 35 references in paper A. Chuchalin G., А. Чучалин Г. (2014) “Новые перспективы в терапии бронхиальной астмы // Bronchial asthma: novel therapeutic approaches” / spz:neicon:pulmonology:y:2011:i:4:p:5-12

1
Архипов В.В., Цой А.Н., Гавришина Е.В. Клинико-экономическая модель базисной терапии бронхиальной астмы. Клиническая медицина 2007; 2: 63–67.
(check this in PDF content)
2
Abbas A.K., Lichtman S.P. Cellular and molecular immunology. 6thed. Amsterdam: Elsevier; 2010.
(check this in PDF content)
3
Lee, S.J., Chinen J., Kavanaugh A.Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines and immunoglobulin's. J. Allergy Clin. Immunol. 2010; 125 (Suppl. 2); S314–323.
(check this in PDF content)
4
Чучалин А.Г., Раудла Л.А., Татарский А.Р., Лебедин Ю.С. Перспективы развития экстракорпоральной специфической иммуносорбции в лечении больных атопической бронхиальной астмой. Сборник: Тезисы докладов на научно-практической конференции врачей-пульмонологов Сибири и Дальнего Востока "Актуальные вопросы реабилитации больных с патологией органов дыхания". Барнаул; 1989. 46–47.
(check this in PDF content)
5
Василов Р.Г.Основные механизмы регуляции синтеза IgE. Новости прикладной иммунологии и аллергологии 1998; 2: 4–5.
(check this in PDF content)
6
Shields R.L. et al.Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. Int. Arch. Allergy Immunol. 1995; 107: 412–413.
(check this in PDF content)
7
Noga O., Hanf G., Kunkel G., Kleine)Tebbe J. Basophil histamine release decreases during omalizumab therapy in allergic asthmatics. Int. Arch. Immunol. 2008; 146 (1): 66–70.
(check this in PDF content)
8
Rudolf M.P., Zuercher A.W., Nechansky A. et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. J. Immunol. 2000; 165 (2): 813–819.
(check this in PDF content)
9
Hayashi N., Tsucamoto Y., Sallas W., Lowe P.A mechanism-based bimding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Brit. J. Clin. Pharmacol. 2006; 63 (5): 548–561.
(check this in PDF content)
10
Holgate S.T., Chuchalin A.G.Efficacy a. safety of recombinant anti-immunoglobulin E antibody in severe allergic asthma, 2004.
(check this in PDF content)
11
Genentech. Xolair®(omalizumab) for subcutaneous use prescribing information. South San Francisco, CA: Genetic Engineering Technology, Inc.; 2008 Jul.
(check this in PDF content)
12
Casale T.B., Bernstein I.L., Busse W.W. et al.Use of an antiIgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 1997; 100: 110–121.
(check this in PDF content)
13
Сучкова Ю.Б.Отдаленные результаты применения моноклональных анти-IgE-антител в комплексной терапии тяжелой неконтролируемой атопической бронхиальной астмой: Дис. ... канд. мед. наук. М.; 2010.
(check this in PDF content)
14
Bousquet J., Cabrera P., Berkman N. et al.The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbation and emergency medical visits in patients with severe persistent asthma. Allergy 2005; 60: 303–308.
(check this in PDF content)
15
Limb S.L., Starke P.R., Lee C.E., Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J. Allergy Clin. Immunol. 2007; 120: 1378–1381.
(check this in PDF content)
16
Сох L.S. How safe are the biologicals in treating asthma and rhinitis? Allergy, asthma, clin. Immunol. 2009; 5 (1): 4.
(check this in PDF content)
17
Singh J., Kraft M. Anti-IgE and other antibody targets in asthma. Handb. Exp. Pharmacol. 2008; 181: 257–288.
(check this in PDF content)
18
Leckie M.J., Brinke A., Diamant Z. et al.Effects of interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness and the late asthmatic response. Lancet 2000, 356: 2144–2148.
(check this in PDF content)
19
Flood)Page P., Swenson C., Faiferman I. et al. A study of evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Resp. Crit. Care Med.
(check this in PDF content)
20
7; 176: 1062–1071. 20.Kips J.C., O`Conner B.J., Langley S.J. et al.Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 2003; 167: 1655–1559.
(check this in PDF content)
21
Haldar P., Brightling C.E., Hargadon B. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma N. Engl. J. Med. 2009; 360: 973–984.
(check this in PDF content)
22
Koike M., Nakamura K., Furuya A. et al.Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum. Antibodies 2009; 18: 17–27.
(check this in PDF content)
23
Busse W.W., Katial R., Gossage D. et al.Safety profile, pharmacokinetics and biological activity MEDI-563, anti-IL-5 receptor alpha antibody, in phase 1 study of subjects with mild asthma. J. Allergy Clin. Immunol. 2010; 125: 1237–1244.
(check this in PDF content)
24
Gruenberg D., Busse W.W. Biological therapies for asthma. Curr. Opin. Pulm. Med. 2010; 16: 19–24.
(check this in PDF content)
25
Erin E.M., Leaker B.R., Nicholson G.C. et al.The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 753–762.
(check this in PDF content)
26
Wenzel S.E., Barnes P.J., Bleecker E.R. et al.A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blocked in severe persistent asthma. Am. J. Respir. Crit. Care Med. 2009; 179: 549–558.
(check this in PDF content)
27
Lee S.J., Chinen J., Kavanaugh A. Immunomodulator therapy: monoclonal antibodies, fusion proteins, cytokines and immunoglobulins. J. Allergy Clin. Immunol. 2010; 125 (Suppl. 2): S314–323.
(check this in PDF content)
28
Howarth P.H., Babu K.S., Arshad H.S. et al.Tumor necrosis factor (TNF-alpha) as a novel therapeutic target in symptomatic corticosteroid dependet asthma. Thorax 2005; 60: 1012–1018.
(check this in PDF content)
29
Doherty T., Broide D. Cytokines and growth factors in airway remodeling in asthma. Curr. Opin. Immunol. 2007; 19: 676–680.
(check this in PDF content)
30
Busse W.W., Israel E., Nelson H.S. et al.Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 1002–1008.
(check this in PDF content)
31
Hart T.K., Blackburn M.N., Brigham)Burke M. et al.Preclinical efficacy and safty of pascolizumab: a humanized antiinterleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 2002; 130: 93–100.
(check this in PDF content)
32
Long A.A.Monoclonal antibodies and other biological agents in treatment of asthma. MAbs 2009; 1: 237–246.
(check this in PDF content)
33
Poole J.A., Meng J., Reff M. et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 2005; 116: 780–788.
(check this in PDF content)
34
Kon O.M., Sihra B.S., Compton C.H. et al.Randomized dose-ranging placebo-controlled study of chemeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998; 352: 1109–1113.
(check this in PDF content)
35
Corren J., Busse W., Meltzer E.O. et al. A randomized controlled phase 11 study of AMG317, an IL-4R-alpha antagonist in patients with asthma. Am. J. Respir. Crit. Care Med. 2010; 181: 788–796. Информация об авторе
(check this in PDF content)